Market Place
Sourcing Support
Galderma’s Nemluvio Shows 3-Year Control in Prurigo Nodularis
27 Feb 2026 //
PHARMIWEB
Galderma Launches ‘We Are All Sculptra’ Regeneration Campaign
12 Feb 2026 //
BUSINESSWIRE
Galderma Announces FDA BLA Acceptance Of RelabotulinumtoxinA
02 Feb 2026 //
BUSINESSWIRE
Galderma Showcases Broadest Injectables Portfolio at IMCAS 2026
22 Jan 2026 //
BUSINESSWIRE
Galderma Plans To Spend $650M On Us-Based Manufacturing
23 Oct 2025 //
FIERCE PHARMA
EADV 2025: Galderma`s Latest Advances in Sensitive Skin and Itch
10 Sep 2025 //
BUSINESSWIRE
Galderma Reveals Data on Efficacy of Injectable After Weight Loss
17 Jul 2025 //
BUSINESSWIRE
Galderma Starts Trials for Nemolizumab in Systemic Sclerosis
25 Jun 2025 //
BUSINESSWIRE
ICD 2025: Nemluvio® Shows Long-Term Safety, Symptom Relief
18 Jun 2025 //
BUSINESSWIRE
Galderma Nemluvio Gets NICE Nod for Atopic Dermatitis
12 Jun 2025 //
BUSINESSWIRE
Nemluvio Long-Term Data Show Gains in Atopic Dermatitis
06 Jun 2025 //
BUSINESSWIRE
Galderma Launches Atopic Dermatitis Awareness Drive
22 Apr 2025 //
PR NEWSWIRE
AMWC 2025: Galderma Innovates with Aesthetic Portfolio Updates
20 Mar 2025 //
BUSINESSWIRE
Galderma Hits $4.41B Sales, $1.03B EBITDA In 2024
06 Mar 2025 //
BUSINESSWIRE
Galderma to Present Updates on Dermatology Portfolio
03 Mar 2025 //
BUSINESSWIRE
Galderma’s Nemluvio® (Nemolizumab) Approved in EMA
15 Feb 2025 //
BUSINESSWIRE
Galderma Phase IIIb Data Shows Rapid, Long-Lasting Relfydess
30 Jan 2025 //
BUSINESSWIRE
Galderma Receives FDA Approval for Nemluvio For Atopic Dermatitis
14 Dec 2024 //
BUSSINESSWIRE
CHMP Recommends Galderma’s Nemolizumab For Atopic Dermatitis
13 Dec 2024 //
BUSINESSWIRE
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology
28 Nov 2024 //
BUSINESSWIRE
Galderma To Share Nemolizumab Data At EADV 2024 Sessions
25 Sep 2024 //
BUSINESSWIRE
FDA Approves Galderma`s Nemluvio For Adult Prurigo Nodularis
14 Aug 2024 //
BUSINESSWIRE
Galderma`s Nemolizumab Shows Positive Results In Atopic Dermatitis
24 Jul 2024 //
BUSINESSWIRE
Galderma Granted Key Manufacturing License Updates
19 Jun 2024 //
BUSINESSWIRE
Galderma Filings For Nemolizumab In 4 More Countries
07 May 2024 //
BUSINESSWIRE
CORRECTING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab
14 Feb 2024 //
BUSINESSWIRE
Galderma Announces Regulatory Filing Acceptance for Nemolizumab
13 Feb 2024 //
BUSINESSWIRE
Results From Galderma’s PIIIb Trials Demonstrate Effect of RelabotulinumtoxinA
30 Nov 2023 //
BUSINESSWIRE
Galderma Phase III Data Published in the New England Journal of Medicine
26 Oct 2023 //
BUSINESSWIRE
Phase III Trials Demonstrate Nemolizumab’s Efficacy in Atopic Dermatitis
11 Oct 2023 //
BUSINESSWIRE
Galderma`s liquid botulinum toxin bid nixed by FDA
03 Oct 2023 //
FIERCE PHARMA
PIII Results Demonstrate nemolizumab’s Impact on Prurigo Nodularis
18 Mar 2023 //
BUSINESSWIRE
